34 North Quay
Douglas IM1 4LB
Isle of Man
44 20 7907 9314
https://www.apollon.org.uk
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Stephen D. Barnhill Jr., M.D. | Chairman & CEO | N/A | N/A | 1959 |
Mr. Stene Jacobs | Head of Corporate Development & COO | N/A | N/A | N/A |
Dr. Herbert A. Fritsche Jr., M.D., Ph.D. | Chief Science Officer, Member of Advisory Board, Consultant & Director | N/A | N/A | 1941 |
Mr. Paul Burke | CEO of Apollion Formularies Jamaica | N/A | N/A | N/A |
Apollon Formularies PLC operates as a medical cannabis pharmaceutical company. It offers hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products, such as cannabis oil vape, oral tincture, and perscribed capsules under the Apollon NAUSEA, Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER names. Apollon Formularies PLC was founded in 2014 and is based in Douglas, the United Kingdom.
Apollon Formularies PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.